Key Drivers
- EBITDA Improvement
- Debt Burden
- Weak Coverage
AIAI Summary
BLCO's improving growth, 13% EBITDA margin, and positive free cash flow suggest a credible operating turnaround, but the equity remains constrained until these gains consistently lift interest coverage above 1x against its $5.1B debt load; investors should wait for durable cash conversion and deleveraging before assigning a full rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •EBITDA Improvement
- •Debt Burden
- •Weak Coverage
BLCO shows improving profitability and cash flow at a low valuation, but high debt, weak interest coverage, and intangible-heavy assets warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Neutral momentum
BLCO's last-month downtrend and lower highs favor caution unless it reclaims $17.55–$17.80, while a break below $17.13–$17.20 could extend losses.
Declined from $18.14 peak on 2026-09-03
Sentiment & News
Key News Insights:
- •Phase III Progress
- •SeeLyra Approval
- •Lens Performance
Bausch + Lomb advanced its pipeline and surgical portfolio with Phase III progress, CE Mark approval for SeeLyra, and supportive lens data, strengthening its eye-care growth outlook.
The updates reinforce Bausch + Lomb's competitive position across dry eye, surgical devices, and premium intraocular lenses
Similar Companies in Healthcare
Other companies in the same sector with AI ratings